Are You Interested In Investing In NeuroBo Pharmaceuticals Inc. (NRBO)? Check This Out First


As of Wednesday close, NeuroBo Pharmaceuticals Inc.’s (NASDAQ:NRBO) stock was up $0.43, moving up 35.83 percent to $1.63. The average number of shares traded per day over the past five days has been 9,790,440 shares. 2 times new highs have been achieved over the past 5 days, with a $0.2600 gain in that time frame. In the last twenty days, the average volume was 7,098,025, while in the previous 50 days, it was 3,273,164.

Since last month, NRBO stock retreated -81.35%. Shares of the company fell to $1.1300 on 11/21/22, the lowest level in the past month. A 52-week high of $63.85 was reached on 09/13/22 after having rallying from a 52-week low of $1.13. Since the beginning of this year, NRBO’s stock price has dropped by -95.55% or -$34.9700, and marked a new high 3 times. However, the stock has declined by -97.45% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Financial Health

In the three months ended September 29, NeuroBo Pharmaceuticals Inc.’s quick ratio stood at 4.70, while its current ratio was 4.70, showing that the company is able to pay off its debt. Based on annual data, NRBO earned $14000.0 in gross profit and brought in $15.3 million in revenue.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected NeuroBo Pharmaceuticals Inc. to report -$5.4 quarterly earnings, the actual figure was -$4.8 per share, beating the consensus estimate by 11.10%. During the quarter, the company generated -$3.1 million in EBITDA. The liabilities of NeuroBo Pharmaceuticals Inc. were 1.62 million at the end of its most recent quarter ended September 29. The value of shareholders’ equity is $6.5 million.

Technical Picture

This quick technical analysis looks at NeuroBo Pharmaceuticals Inc.’s (NRBO) price momentum. With a historical volatility rate of 379.46%, the RSI 9-day stood at 29.45% on 23 November.

With respect to its five-day moving average, the current NeuroBo Pharmaceuticals Inc. price is up by +18.98% percent or $0.2600. At present, NRBO shares trade -79.90% below its 20-day simple moving average and -88.19% percent below its 100-day simple moving average. However, the stock is currently trading approximately -90.33% below its SMA50 and -94.00% below its SMA200.

Stochastic coefficient K was 10.00% and Stochastic coefficient D was 4.53%, while ATR was 0.5945. Given the Stochastic reading of 26.74% for the 14-day period, the RSI (14) reading has been calculated as 30.72%. As of today, the MACD Oscillator reading stands at 0.0144, while the 14-day reading stands at -0.1438.

Analyst Ratings

H.C. Wainwright launched its rating on NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) to a Buy in a note to investors on June 15, 2020. NeuroBo Pharmaceuticals Inc. (NRBO) has been rated Buy by analysts. According to 0 brokerage firms, NRBO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate NeuroBo Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.

With a median target price of $480.00, the current consensus forecast for the stock is $480.00 – $480.00. Based on these forecasts, analysts predict NeuroBo Pharmaceuticals Inc. (NRBO) will achieve an average price target of $480.00.


Please enter your comment!
Please enter your name here